Literature DB >> 21933279

Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies.

Xingbing Wang1, Huilan Liu, Lailing Li, Liangquan Geng, Kaiyang Ding, Xin Liu, Juan Tong, Weibo Zhu, Zimin Sun.   

Abstract

Pre-engraftment syndrome (PES) after umbilical cord blood transplantation (CBT) remains poorly characterized, and the prognosis and appropriate management are unclear. Therefore, we retrospectively analyzed the incidence, risk factors, manifestations, and clinical outcomes of PES in CBT recipients, who had been treated for hematologic malignancies at our transplantation center. PES was defined as unexplained fever higher than 38.3°C that is not associated with documented infection and unresponsive to antimicrobial manipulations and/or unexplained erythematous skin rash occurring prior to neutrophil engraftment. A total of 81 patients (median 18 yr, range 3-48) received either myeloablative (n=72) or non-myeloablative (n=9) conditioning. Neutrophil engraftment was achieved in 69 of the 81 cases [86.2%, 95% confidence interval (CI)=78.9-94.1%], and the median time to more than 0.5 × 10(9) /L ANC was 19 d (range, 12-39). Fifty-one patients (63.0%) developed PES at a median of 7d (range 3-15) post-transplant: 46 patients had both rash and unexplained fever; one patient had unexplained fever alone; and four patients had rash only. Forty-seven patients (92.2%) received IV methylprednisolone (MP) at a median dose of 1 mg/kg (range 0.4-3). All patients treated with MP responded as evidenced by fever resolution combined with resolution of rash. All patients with PES had high serum levels of C-reactive protein (CRP), which were significantly reduced after effective steroid treatment. Univariate analysis identified myeloablative conditioning and younger age as significant risk factors for developing PES. Cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) in the PES+ and PES- groups was 51.5% (95% CI=38.0-70.0%) and 17.0% (95% CI=6.9-41.7%), respectively. In a multivariate analysis, we found significantly increased risk of grade II-IV aGVHD among PES patients (P=0.041). However, PES was not associated with sustained donor engraftment, the day to neutrophil recovery, chronic graft-versus-host disease, transplant-related mortality at day 180, and overall survival. Despite of the inherent limitations of this small retrospective study, PES seemed to be common after CBT and associated with high incidence of aGVHD.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933279     DOI: 10.1111/j.1600-0609.2011.01709.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis.

Authors:  Kittika Poonsombudlert; Jakrin Kewcharoen; Chattip Prueksapraopong; Nath Limpruttidham
Journal:  Hawaii J Health Soc Welf       Date:  2020-06-01

Review 2.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

3.  Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease.

Authors:  Matthew R Kudek; Ryan Shanley; Nicole D Zantek; David H McKenna; Angela R Smith; Weston P Miller
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-02       Impact factor: 5.742

4.  Risk factors of CMV infection in patients after umbilical cord blood transplantation: a multicenter study in China.

Authors:  Juan Tong; Zimin Sun; Huilan Liu; Liangquan Geng; Changcheng Zheng; Baolin Tang; Kaidi Song; Wen Yao; Xin Liu
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

5.  Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.

Authors:  Toshihiro Miyamoto; Shuichiro Takashima; Koji Kato; Ken Takase; Goichi Yoshimoto; Shuro Yoshida; Hideho Henzan; Koichi Osaki; Tomohiko Kamimura; Hiromi Iwasaki; Tetsuya Eto; Takanori Teshima; Koji Nagafuji; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-09-29       Impact factor: 2.490

6.  Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Authors:  Lawrence Chang; David Frame; Thomas Braun; Erin Gatza; David A Hanauer; Shuang Zhao; John M Magenau; Kathryn Schultz; Hemasri Tokala; James L M Ferrara; John E Levine; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

7.  Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation.

Authors:  Kyle R Brownback; Steven Q Simpson; Joseph P McGuirk; Tara L Lin; Sunil Abhyankar; Siddhartha Ganguly; Omar S Aljitawi
Journal:  Ann Hematol       Date:  2013-12-18       Impact factor: 3.673

Review 8.  Pre-engraftment syndrome: clinical significance and pathophysiology.

Authors:  Young-Ho Lee; Wee-Jin Rah
Journal:  Blood Res       Date:  2016-09-23

9.  Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients.

Authors:  Linlin Jin; Zimin Sun; Huilan Liu; Xiaoyu Zhu; Yonggang Zhou; Binqing Fu; Xiaohu Zheng; Kaidi Song; Baolin Tang; Yun Wu; Jiang Zhu; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  Nat Commun       Date:  2021-07-06       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.